

Melatonin prolonged release tablets (Circadin® and Slenyto®) for the treatment of persistent chronic sleep disorders in adults and children

The Pan Mersey Area Prescribing Committee recommends the prescribing of melatonin prolonged release tablets (Circadin® and Slenyto®) for the treatment of persistent chronic sleep disorders in the circumstances below where sleep hygiene measures have been insufficient.

AMBER following specialist initiation

The patient and or parent must be offered a structured sleep behavioural intervention programme if appropriate and available prior to consideration of melatonin. If a structured sleep behavioural intervention programme is not available, sleep hygiene must be optimised first. The approach outlined in this document does not apply to patients with Parkinson's disease (PD). Sleep disorders associated with PD can be managed by a PD specialist in accordance with NICE NG71 Parkinson's disease in adults. Management options include the initiation of melatonin.

Melatonin should only be considered if the patient experiences

- <6 hours of continuous sleep persistently for at least 3 months AND/OR
- >0.5 hour sleep latency on at least 3 out of 5 work/school nights per week for 2 weeks.

AND there must ALSO be evidence that the patient has been diagnosed with a persistent chronic sleep disorder (e.g. insomnia or delayed sleep phase syndrome) associated with at least one of the following:

- Attention Deficit Hyperactivity Disorder (ADHD)
- Autistic Spectrum Disorders (ASD)
- Cerebral Palsy
- Chronic fatigue syndrome (CFS)/ myalgic encephalomyelitis (ME) (or encephalopathy)
- Complex neurodevelopmental disorders (i.e., Angelman's syndrome, Rett's syndrome, Smith Magenis syndrome (SMS), tuberous sclerosis complex, fragile X syndrome, foetal alcohol spectrum disorder (FASD))
- Global developmental delay / learning disability
- Parkinson's disease with REM sleep disorder.

Circadin® is licensed for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over. The uses outlined in this document are off-label. Slenyto® is licensed for the treatment of insomnia in children and adolescents ages 2-18 with ASD and/or SMS. Slenyto® should only be used in these indications, or for patients unable to swallow Circadin® with persistent chronic sleep disorder associated with conditions specified in this statement (off label).

IMPORTANT This statement does not include other forms of licensed melatonin such as melatonin 2mg capsules (Colonis®), melatonin 3mg tablets (Colonis®) or melatonin 1mg/ml liquid (Colonis®) – designated RED, which are licensed in jet lag for short term use. **The melatonin 1mg/ml liquid has been assessed and the quantities of propylene glycol may be excessive for some children.** Other unlicensed melatonin preparations or melatonin food supplements remain RED due to the variation in quality, cost to primary care and lack of evidence regarding suitability of excipients in children. **For certain patients, unlicensed melatonin may be required i.e., patients with feeding tubes. In this circumstance prescribing, monitoring and review responsibilities will be held by specialist.**

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.

Melatonin prolonged release tablets (Circadin® and Slenyto®) for the treatment of persistent chronic sleep disorders in adults and children

Effectiveness

Melatonin is a pineal hormone that may affect sleep pattern. Clinical experience suggests that when appropriate behavioural sleep interventions fail, melatonin may be of value for treating sleep disorders secondary to conditions listed above [1].

There are multiple randomised controlled trials, meta-analyses and systematic reviews which assess the safety and efficacy of melatonin. The evidence for the use of melatonin varies in quality depending on the condition being studied. There is good quality evidence supporting the use of melatonin in sleep disorders secondary to ASD and learning disabilities [2-9]. The evidence for treating sleep disorders secondary to other neurodevelopmental disorders supports the use of melatonin [10-17], the studies however have low patient numbers due to the heterogeneity of the conditions studied and their rare nature. Evidence for the use of melatonin in sleep disorders caused by visual impairment, acquired brain injury and epilepsy is poor and/or lacking.

The National Institute of Health and Care Excellence (NICE) CG53[18], NG62[19], NG11[20] supports melatonin use for sleep problems secondary to chronic fatigue syndrome/myalgic encephalomyelitis, cerebral palsy and learning disability respectively in children and young people.

NICE CG170 and The Scottish Intercollegiate Guidelines Network (SIGN) SIGN 145[21-22] recommend melatonin to aid sleep for autistic children following consultation with a specialist paediatrician or psychiatrist with expertise in the management of autism or paediatric sleep medicine. It should be used in conjunction with non-pharmacological interventions and be regularly reviewed to evaluate the ongoing need for a pharmacological intervention and to ensure that the benefits continue to outweigh the side effects and risks.

The All Wales Medicines Strategy Group (AWMSG) have recommended the use of Slenyto® in line with its marketing authorisation only where the approved Wales Patient Access Scheme is utilised [23].

Safety

Melatonin therapy is well tolerated from primary literature and from clinical experience. The most commonly reported side effects tend to be mild and transient.

A study by Malow et al showed that long term melatonin therapy continues to be effective and has shown that there are no significant effects on growth or pubertal development [24]. This has also been corroborated by Van Geijswijk et al [25] in an earlier study. These studies followed up children after 2 and 3.1 years of melatonin therapy respectively.

Cost

Slenyto®: £0.69/mg. Available as 1mg (60 pack) or 5mg tablets (30 pack)

Circadin®: £0.26/mg. Available as 2mg tablets (30 pack)

Estimated current total Pan Mersey spend per annum: £2,203,318.

Projected spend¹: Between £3,772,729² and £5,835,505³ plus cost of sleep behavioural intervention service.

1. Projected spend based on drug tariff price. Cost range given as unable to accurately predict number of children who will be on Slenyto® due to inability to swallow Circadin®. Hospital contract prices and rebate schemes available.
2. Based on adults on unlicensed formulations changing to Circadin® tablets. Slenyto® used in children who fit its licensed indications. All other children switched or remain on Circadin®
3. Based on adults on unlicensed formulations changing to Circadin®MR tablets and all children switched to Slenyto®

For comparison

Melatonin 3mg tablets (Colonis Pharma Ltd): £0.72/mg

Melatonin 1mg/ml oral solution (Colonis Pharma Ltd): £0.87/mg

Melatonin 2mg capsule (Colonis Pharma Ltd): £0.95/mg

The Scottish Medicines Consortium (SMC) has not recommended Slenyto® for the treatment of insomnia in children and adolescents ages 2-18 with ASD/SMS [26]. The SMC also commented on the fact that they did not receive sufficiently robust clinical and economic analysis to gain acceptance by the SMC.

Patient factors

Melatonin prolonged release therapy should always be recommended over instant release (or crushed prolonged release tablets) as instant release therapy can cause sleep phase shifting [27]. Longer term safety data only exists for prolonged release melatonin.

Prescribing should reflect the [STOMP/STAMP](#) pledge that children and young people with a learning disability, autism or both are able to access appropriate medication but are not prescribed inappropriate psychotropic medication. Regular and timely reviews should be undertaken.

See [prescribing support documentation](#) for more extensive information to guide formulation choice.

Prescribing information

See [prescribing support documentation](#)

References

1. Wurtman, R. *Physiology and available preparations of melatonin*. https://www.uptodate.com/contents/physiology-and-available-preparations-of-melatonin?search=melatonin&source=search_result&selectedTitle=1~110&usage_type=default&display_rank=1 (accessed 29/8/19).
2. Gringras, P. et al. Efficacy and Safety of Paediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. *J Am Acad Child Adolesc Psychiatry*. 2017;56(11):948-95
3. Delyens, G. et al. Sleep Disturbance in Autism Spectrum Disorders. *Rev J Autism Dev Disorder*. 2015; 2:343-356
4. Cuomo, Belinda M et al Effectiveness of Sleep-Based Interventions for Children with Autism Spectrum Disorder: A Meta-Synthesis. *Pharmacotherapy*; May 2017; vol. 37 (no. 5); p. 555-578
5. Braam W et al. Melatonin treatment in individuals with intellectual disability and chronic insomnia: A randomized placebo-controlled study. *Source Journal of Intellectual Disability Research*; Apr 2008; vol. 52 (no. 3); p. 256-264
6. Dodge N. N. & Wilson G. A. Melatonin for treatment of sleep disorders in children with developmental disabilities. *Journal of Child Neurology*. 2001; 16, 581-4.
7. Coppola G., Iervolino G., Mastrosimone M., La Torre G., Ruiu F. & Pascotto A. Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. *Brain and Development*. 2004; 26, 373-6.
8. McArthur A. J. & Budden S. S. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. *Developmental Medicine & Child Neurology*. 1998; 40 186-92
9. Garstang J. & Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. *Child: Care, Health and Development*. 2006; 32 585-9.
10. Appleton RE, Jones AP, Gamble C, et al. The use of Melatonin in children with neurodevelopmental disorders and impaired sleep; a randomised, double blind, placebo-controlled, parallel study (MENDS) *Neuropediatrics*. 2015; Vol. 46 No. 3.
11. Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. *J Pineal Res* 2008; 44:57-64.
12. McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. *Dev Med Child Neurol* 1998; 40:186-92.
13. Braam W, Didden R, Smits MG, Curfs LM. Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial. *J Child Neurol* 2008; 23:649-54
14. Masi G et al Effects of melatonin in children with attention-deficit/hyperactivity disorder with sleep disorders after methylphenidate treatment. *Neuropsychiatric Disease and Treatment*; 2019; vol. 15 ; p. 663-667
15. Weiss MD, Wasdell MB, Bomben MM et al.. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. *J Am Acad Child Adolesc Psychiatry*. 2006;45(5):512-9.
16. Van der Heijden KB, Smits MG, Van Someren EJ, et al. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. *J Am Acad Child Adolesc Psych* 2007; 46: 233-41.
17. Hoebert M, van der Heijden KB, van Geijlswijk IM, et al. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. *J Pineal Res* 2009 Aug; 47 (1): 1-7
18. [NICE Clinical Guideline 53 \(August 2007\) Chronic fatigue syndrome/myalgic encephalomyelitis - diagnosis and management in adults and children](#)
[Chronic fatigue syndrome/myalgic encephalomyelitis](#)
19. NICE Guideline 62 Cerebral palsy in under 25s: assessment and management. Available from: <https://www.nice.org.uk/guidance/NG62/chapter/Recommendations#sleep-disturbances>. Accessed 27 August 2021
20. NICE Guideline 11 (2015) Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. Available from: <https://www.nice.org.uk/guidance/ng11/chapter/Recommendations#interventions-for-sleep-problems>.
21. [National Institute of Health and Care Excellence \(NICE\). Clinical guideline number 170, Autism spectrum disorder in under 19s: support and management, August 2013.](#)
22. Scottish Intercollegiate Guidelines Network. Assessment, diagnosis and interventions for autism spectrum disorders (ASD): A national clinical guideline (SIGN 145). Available at <https://www.sign.ac.uk/assets/sign145.pdf>
23. Melatonin (Slenyto®) - All Wales Medicines Strategy Group. Available from: <https://awmsg.nhs.wales/medicines-appraisals-and-guidance/medicines-appraisals/melatonin-slenyto1/>
24. Malow et al. Sleep, Growth, and Puberty After Two Years of Prolonged-Release Melatonin in. *Journal of the American Academy of Child & Adolescent*. 2020
25. van Geijlswijk IM, Mol RH, Egberts TC et al. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia. *Psychopharmacology (Berl)* 2011; 216:111.
26. Melatonin (Slenyto®). Scottish Medicine Consortium. 2019 Available from: <https://www.scottishmedicines.org.uk/medicines-advice/melatonin-slenyto-full-smc2168>
27. Gringras P et al 2012; Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo-controlled trial. *BMJ* 2012;345:1-16